MyPivots
Sign In
Home / Dictionary / Morbidity Rate
✕

Morbidity Rate

The morbidity rate is an important indicator of the health of a population and can be used to track the incidence of diseases and conditions over time. It can also be used to compare the health of different populations and to identify areas where there is a need for more preventive care or treatment.

What is Morbidity Rate?

There are a number of different ways to calculate the morbidity rate. The most common method is to use the following formula:

Morbidity Rate = Number of New Cases / Total Population at Risk

The number of new cases is the number of people who are diagnosed with the disease or condition for the first time during the specified period of time. The total population at risk is the number of people who are at risk of developing the disease or condition.

The morbidity rate can be used to track the incidence of a disease or condition over time. For example, the following table shows the morbidity rate for breast cancer in the United States from 1999 to 2023, expressed as new cases per 100,000 women and age-adjusted to the 2000 U.S. standard population (SEER 12 registries, National Cancer Institute):

YearMorbidity Rate
1999138.8 per 100,000 women
2000134.1 per 100,000 women
2001136.0 per 100,000 women
2002133.1 per 100,000 women
2003123.7 per 100,000 women
2004124.6 per 100,000 women
2005124.6 per 100,000 women
2006122.6 per 100,000 women
2007126.3 per 100,000 women
2008126.8 per 100,000 women
2009127.4 per 100,000 women
2010123.9 per 100,000 women
2011127.4 per 100,000 women
2012126.8 per 100,000 women
2013127.5 per 100,000 women
2014127.0 per 100,000 women
2015129.2 per 100,000 women
2016129.0 per 100,000 women
2017130.3 per 100,000 women
2018132.2 per 100,000 women
2019135.7 per 100,000 women
2020122.1 per 100,000 women
2021139.4 per 100,000 women
2022136.1 per 100,000 women
2023136.5 per 100,000 women

As you can see, the morbidity rate for breast cancer in the United States fell sharply from 1999 to 2003 — a drop widely attributed to reduced use of hormone replacement therapy after the Women's Health Initiative results in 2002 — then bottomed out in the mid-2000s and has risen slowly since, by about 0.7% per year over 2014–2023. The sharp dip in 2020 reflects COVID-19 disrupting screening and diagnosis rather than a true fall in disease, and the rate rebounded in 2021 as screening caught up.

The morbidity rate can also be used to compare the health of different populations. For example, the following table shows the morbidity rate for breast cancer in the United States and Canada from 1999 to 2022. Note that each country age-standardizes to its own reference population (the 2000 U.S. standard for the United States; the 2011 Canadian standard for Canada, excluding Quebec and Nova Scotia), so the two columns are best read as each country's trend over time rather than a like-for-like comparison of levels:

YearUnited StatesCanada
1999138.8 per 100,000 women148 per 100,000 women
2000134.1 per 100,000 women140 per 100,000 women
2001136.0 per 100,000 women139 per 100,000 women
2002133.1 per 100,000 women144 per 100,000 women
2003123.7 per 100,000 women136 per 100,000 women
2004124.6 per 100,000 women136 per 100,000 women
2005124.6 per 100,000 women137 per 100,000 women
2006122.6 per 100,000 women136 per 100,000 women
2007126.3 per 100,000 women138 per 100,000 women
2008126.8 per 100,000 women134 per 100,000 women
2009127.4 per 100,000 women138 per 100,000 women
2010123.9 per 100,000 women143 per 100,000 women
2011127.4 per 100,000 women144 per 100,000 women
2012126.8 per 100,000 women139 per 100,000 women
2013127.5 per 100,000 women139 per 100,000 women
2014127.0 per 100,000 women140 per 100,000 women
2015129.2 per 100,000 women138 per 100,000 women
2016129.0 per 100,000 women140 per 100,000 women
2017130.3 per 100,000 women139 per 100,000 women
2018132.2 per 100,000 women141 per 100,000 women
2019135.7 per 100,000 women142 per 100,000 women
2020122.1 per 100,000 womenNot published
2021139.4 per 100,000 women143 per 100,000 women
2022136.1 per 100,000 women149 per 100,000 women

Canada's rate has been broadly flat across the period, ending it close to where it began, while the United States saw a decline and then a renewed rise. Sources: SEER Cancer Stat Facts, National Cancer Institute; Canadian Cancer Registry, Statistics Canada.

Why Financial Markets Care

Morbidity measures illness rather than death, and illness is where most healthcare money changes hands. A person who dies quickly generates few bills; a person who lives for years with a chronic condition generates them continuously. That makes morbidity rates a direct input into the earnings of several sectors:

  • Health insurers. Morbidity assumptions are the core of underwriting and pricing. Expected incidence and treatment rates for diseases across an insured population determine premiums, reserves, and the medical loss ratio. When actual morbidity runs hotter than priced — a surge in diagnoses, a utilization rebound after deferred care, rapid uptake of an expensive new drug class — claims costs rise faster than premiums and insurer earnings miss. When it runs cooler, the same math works in reverse.
  • Life, disability, and long-term care insurers. Disability income and long-term care policies pay on morbidity, not mortality: they are triggered by illness and inability to work or live independently. Underestimating how long policyholders would live with disabling conditions badly hurt long-term care insurers historically, and morbidity tables sit alongside mortality tables in every actuarial model.
  • Hospitals and healthcare providers. Disease incidence is demand. Rising incidence of cancer, diabetes, or heart disease means more admissions, procedures, imaging, and outpatient visits. The catch is payer mix and capacity: the same morbidity trend can be a revenue tailwind for a hospital system and a cost headwind for the insurers and employers paying it.
  • Pharmaceutical, biotech, and medical device companies. Incidence defines the addressable market for a therapy. Drug pipelines, trial design, and revenue forecasts are built on epidemiology — how many new cases per year, at what stage, in which countries. A sustained rise in a condition's morbidity, such as the recent increase in early-onset cancers, expands the expected market and can re-rate the companies exposed to it.
  • Employers and the wider economy. Morbidity drives absenteeism, disability claims, group health premiums, and labor-force participation. A population that is sicker works less and costs more to employ, which feeds into productivity growth, wage pressure, and ultimately the data central banks watch. The rise in long-term sickness after COVID-19 measurably reduced labor supply in several economies.
  • Governments and bond markets. Public programs bear much of the cost of population illness, so morbidity trends shape long-run Medicare, Medicaid, and national health budgets, and with them deficit projections and the credit outlook for public hospital systems and municipalities.
  • Shock events. Epidemics are morbidity shocks before they are mortality shocks. COVID-19 disrupted markets mainly through illness-driven absence, deferred elective care, and overwhelmed hospitals — effects that hit insurers, providers, travel, and leisure in opposite directions at the same time, and largely reversed as morbidity patterns normalized.
Related definitions
Moral Hazard
Discover by Letter
$